GT1708F / Kintor Pharma - LARVOL DELTA

Treatment with GT1708F, an Oral Smoothened Inhibitor, in Patients with Myeloid Malignancies: A Phase I Study (ASH 2023) - "Our study indicated good safety and tolerability of GT1708F in patients with myeloid malignancies. In addition, a potential efficacy signal of GT1708F for these patients was observed, providing a rationale for further exploration in combination with other therapeutic modalities."

Clinical • P1 data • Acute Myelogenous Leukemia • Anemia • Developmental Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Oncology • Respiratory Diseases

Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China (PRNewswire) - P1 | N=NA | "Kintor Pharmaceutical Limited...announced that its Hedgehog/SMO inhibitor GT1708F had obtained conditional approval to conduct Phase II clinical trial in China by the National Medical Products Administration (NMPA) for treatment of idiopathic pulmonary fibrosis (IPF)....GT1708F completed the Phase I clinical trial in China for hematologic malignancies. The results showed that the GT1708F demonstrated good safety and tolerability, with no dose-limiting toxicity (DLT) and drug-related serious adverse events (SAEs) in patients."

New P2 trial • P1 data • Idiopathic Pulmonary Fibrosis

Kintor Pharmaceutical-B (09939) successfully completed the Phase I clinical trial of GT1708F independently developed by Kintor in the treatment of hematological malignancies [Google translation] - "Zhitong Finance APP news, Kintor Pharmaceutical-B (09939) announced that its self-developed GT1708F (Hedgehog/SMO inhibitor) in the treatment of malignant blood diseases in China Phase I clinical trial (the Phase I clinical trial) was successfully completed. The results showed that GT1708F demonstrated good safety and tolerability, and no dose-limiting toxicity (DLT) or serious adverse event (SAE) related to the study drug occurred in any patient. In the dose-escalation phase, starting from the 180mg dose group, initial efficacy was observed in patients with acute myeloid leukemia (AML) who failed multiple lines of therapy, and the myeloid blasts in AML patients decreased by up to 62% compared with the baseline...The company is currently actively preparing for clinical trial applications for IPF and tumor indications."

New indication • Trial status • Acute Myelogenous Leukemia • Hematological Malignancies • Idiopathic Pulmonary Fibrosis • Oncology

Combination of a clinical stage-hedgehog inhibitor, GT1708, improves Venetoclax-induced apoptosis by down-regulating MCL-1 proteins in AML cells (AACR 2023) - "Although HH inhibitor Glasdegib in combo with low-dose cytarabine achieved FDA approval for AML, Venetoclax (BCL-2 inhibitor/ABT-199) plus a hypomethylating agent (HMA) have been dominating the regimens in AML recently...Furthermore, ABT+Aza (Azacidine/HMA drug) induced more MCL-1 expression than ABT-199...GT1708 has been shown to reduce blast counts in three of 13 AML patients treated with higher doses and demonstrated favorite PK and safety profiles. In brief, these results support the clinical development of GT1708 in combination with ABT-199 in AML patients."

Clinical • IO biomarker • Acute Myelogenous Leukemia • Brain Cancer • CNS Tumor • Glioma • Hematological Malignancies • Leukemia • Medulloblastoma • Oncology • Solid Tumor • GLI1 • MCL1

Kintor Pharmaceutical : Pharma Announces Preclinical Data of GT1708F at AACR 2023 (Market Screener) - "Kintor Pharmaceutical Limited...announced that the latest preclinical data from the company's hedgehog inhibitor GT1708F for the treatment of Acute Myeloid Leukemia (AML) has been selected for presentation at the 2023 American Association of Cancer Research (AACR) Annual Meeting, and the abstract is available on AACR's official website."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Kintor Pharmaceutical Limited Announces 2020 Business Progress and Annual Results (PRNewswire) - “Proxalutamide (GT0918, AR antagonist), a new generation of AR antagonist: The Phase III clinical trial of proxalutamide monotherapy finished recruiting patients on August 4, 2020. We expect to release results later in 2021…In addition, we will continue to advance the clinical development and regulatory process of proxalutamide for the treatment of mCRPC as a single agent and in combination with abiraterone in 2021; Detorsertib (GT0486): The Phase I clinical trial of GT20029 in China will be completed in 2021; The Phase I clinical trial of GT1708F for leukemia in China will be completed in 2021.”

P3 data • Trial completion date • Genito-urinary Cancer • Leukemia • Oncology • Prostate Cancer